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Abstract
Background: Cardiovascular disease (CVD) remains the leading cause of death globally. Primary prevention of CVD
requires cost-effective strategies to identify individuals at high risk in order to help target preventive interventions. An
integral part of this approach is the use of CVD risk scores. Limitations in previous studies have prevented reliable
inference about the potential advantages and the potential harms of using CVD risk scores as part of preventive
strategies. We aim to evaluate short-term effects of providing different types of information about coronary heart disease
(CHD) risk, alongside lifestyle advice, on health-related behaviours.
Methods/Design: In a parallel-group, open randomised trial, we are allocating 932 male and female blood donors with
no previous history of CVD aged 40–84 years in England to either no intervention (control group) or to one of three
active intervention groups: i) lifestyle advice only; ii) lifestyle advice plus information on estimated 10-year CHD risk based
on phenotypic characteristics; and iii) lifestyle advice plus information on estimated 10-year CHD risk based on phenotypic
and genetic characteristics. The primary outcome is change in objectively measured physical activity. Secondary
outcomes include: objectively measured dietary behaviours; cardiovascular risk factors; current medication and healthcare
usage; perceived risk; cognitive evaluation of provision of CHD risk scores; and psychological outcomes. The follow-up
assessment takes place 12 weeks after randomisation. The experiences, attitudes and concerns of a subset of participants
will be also studied using individual interviews and focus groups.
Discussion: The INFORM study has been designed to provide robust findings about the short-term effects of providing
different types of information on estimated 10-year CHD risk and lifestyle advice on health-related behaviours.
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Background
Cardiovascular disease (CVD) remains the leading
cause of death globally [1], with an estimated 17
million deaths from CVD in 2011, or about 3 in
every 10 deaths [2]. Of CVD deaths, 7 million deaths
are due to coronary heart disease (CHD) and 6.2
million due to stroke [3]. The annual number of
people who die from CVD is predicted to reach 23.3
million by 2030 and CVD is projected to remain the
single leading cause of death [4].
Primary prevention strategies often involve CVD
risk scores [5–9] to identify individuals at high esti-
mated risk of CVD in order to target preventive in-
terventions. Risk scores, which are recommended for
use by national guidelines in most countries [10, 11],
are algorithms that calculate an individual’s risk of
CVD by combining information on several different
risk factors. In the United Kingdom, CVD risk assess-
ment tools are implemented in general practitioner
(GP) computer systems [12]. The National Health
Service (NHS) has initiated a programme of CVD risk
reduction (“NHS Health Check”) which includes as-
sessment of CVD risk for all those aged 40–74 years
without pre-existing CVD and related disorders,
although the effectiveness of this approach remains
uncertain [13].
There are several risk factors that increase the risk
of CVD including both non-modifiable factors such
as family history, ethnic origin and gender and modi-
fiable risk factors such as smoking, unhealthy diet,
obesity and diabetes [14, 15]. The UK National Insti-
tute for Health and Care Excellence (NICE) [16] and
the Joint British Societies for the prevention of CVD
[10] recommend primary prevention of CVD through
a focus on interventions that may change the behav-
iour of individuals, such as smoking cessation, redu-
cing alcohol consumption, and increasing physical
activity [17]. The provision of CVD risk information
could afford the opportunity to improve CVD risk
perception among individuals and so motivate a
change in health-related behaviours. There is evidence
to suggest that the provision of phenotypic CVD risk
information improves people’s accuracy of perceived
risk. Systematic reviews have, however, reported that
provision of risk information needs to be accompan-
ied by other tools in order to improve health-related
behaviours and other relevant clinical outcomes [18, 19].
Studies included in previous reviews have been limited by
the use of self-reported (rather than objective) measures
of diet and physical activity.
Recent identification of several genetic risk factors for
CVD has suggested the possibility of supplementing
traditional CVD risk scores with genetic information to
help motivate behaviour change and improve clinical
outcomes [20, 21]. Theoretical models of health-related
behaviour change, such as the Health Belief Model [22],
would predict a positive impact of using such an ap-
proach. Direct-to-consumer genetics companies have
claimed that providing people with such information
could encourage healthy lifestyle choices. Alternatively,
however, provision of such information could induce a
defeatist response, leading to unhealthy lifestyle choices.
A review by Marteau et al. [23] concluded that provision
of genetic risk information generally has little or no ef-
fect on behaviour, although it may have a small effect on
intentions to change behaviour. However, previous stud-
ies of the impact of provision of genetic risk information
have been underpowered and lacked objective measures
of behaviour. Hence, the potential benefits and the po-
tential harms of adding, and communicating, genetic
CVD risk information to phenotypic CVD scores are
unknown.
Using both quantitative and qualitative methods, we
aim to assess the short-term effect of providing different
types of information about CHD risk, alongside lifestyle
advice, on health-related behaviours.
Objectives
Primary objective
The primary objective of the INFORM study is to
evaluate the effect of providing different types of in-
formation about estimated 10-year CHD risk, along-
side lifestyle advice on health-related behaviours over
three months.
Secondary objectives
The secondary objectives are to evaluate the effect of
providing different types of information about CHD
risk, alongside lifestyle advice on objectively measured
dietary behaviour (key secondary objective); cardiovas-
cular risk factors; current medication and healthcare
usage; perceived risk; cognitive evaluation of provision
of CHD risk scores; and psychological outcomes.
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Objectives of the qualitative study
The study also aims to provide rich and detailed infor-
mation which may explain, clarify, support or modify the
quantitative findings.
Methods/Design
Study design
The design of the trial and flow of participants are
shown in Fig. 1. In a parallel-group, open randomised
trial, we are allocating 932 male and female blood do-
nors with no previous history of CVD aged 40–84 years
in England to either no intervention (control group) or
to one of three active intervention groups: i) lifestyle
advice only ii) lifestyle advice plus information on esti-
mated 10-year CHD risk based on phenotypic character-
istics; and iii) lifestyle advice plus information on
estimated 10-year CHD risk based on phenotypic and
genetic characteristics. Lifestyle advice consists of three
sessions of interactive, tailored web-based information.
The qualitative element of the study consists of individ-
ual interviews and focus groups with trial participants at
different time points throughout the trial.
Population
Male and female blood donors aged 40–84 years with no
previous history of CVD.
Setting
The trial is administered at the University of Cambridge.
Participants live in England.
Recruitment
Participants are a subset of those recruited into the
INTERVAL study, an ongoing randomised, multisite trial
that has recruited approximately 50,000 blood donors
from all 25 permanent donor centres of NHS Blood and
Transplant (NHSBT) throughout England. The INTER-
VAL study aims to determine whether donation intervals
can be safely and acceptably decreased to optimise blood
supply while maintaining the health of donors [24].
Blood donors are potentially eligible to participate in the
INTERVAL study if they are aged 18 years or older, fulfil
all normal criteria for blood donation [25] and are will-
ing to donate at one of the permanent NHSBT donation
centres over a period of two years. Participants are ex-
cluded if they do not have internet access and/or are not
Fig. 1 INFORM Trial CONSORT Diagram
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willing to provide an email address for trial correspond-
ence, since the trial mainly collects data via remote and
web-based methods [24]. INTERVAL participants pro-
vide data (via online questionnaires) and blood samples
at the time of joining the study and after two years.
DNA has been extracted from baseline blood samples
for genome-wide genotyping using the Affymetrix “UK
Biobank” Axiom genotyping array. In addition, lipid pro-
files of all participants are being assessed via NMR-
metabolomic assay. At their 2-year anniversary of joining
INTERVAL, a subset of participants, who are willing
and selected to do so, wear a physical activity monitor-
ing device for 7 days (Axivity AX3 3-Axis Logging
Accelerometer®, Axivity, York, UK).
INTERVAL participants are invited to take part in the
INFORM study if they have completed their INTERVAL
2-year follow-up questionnaire and have indicated an
interest in wearing a physical activity monitor. Further-
more, they have to be aged 40–84 years (inclusive); will-
ing to provide a blood sample; have sufficient data
available to the study team for calculation of phenotypic
and genetic risk estimates for CHD (described in detail
below); agree to allow trial staff to contact their GP to
notify them of trial participation and study test results;
have internet access and are willing to provide an email
address for study correspondence; and have a good un-
derstanding of the English language, both written and
oral (study materials are not tailored to support non-
English language speakers). Potential participants are
excluded if they have prior history of CVD (e.g. heart
attack, angina, peripheral arterial disease or stroke,
surgical or percutaneous coronary revascularisation pro-
cedure); a medical condition or disability that means the
participant cannot engage in physical activity; known
pregnancy at time of recruitment; are unable to provide
informed consent; and are currently participating in an-
other interventional clinical trial in cardiovascular risk
or lifestyle modification (e.g. diet, physical activity or
smoking cessation).
Between March 2015 and June 2015, electronic invita-
tions approved by the local ethics committee have been
sent to participants who meet the invitation criteria. The
invitation email message consists of a brief summary
and a personalised weblink to the INFORM screening
and consent questionnaire. It also contains a weblink to
the study website [26], where participant information is
available.
We aim to involve a subset of 30–35 participants in
the INFORM trial to take part in qualitative interviews
and a further subset of 16–36 participants to take part
in 2–3 focus groups. The exact number of the inter-
viewees and focus groups is dependent on saturation of
the data and the willingness of enough participants from
the same area to take part in focus groups. Invitations to
take part in the qualitative interviews and focus groups
are sent to a purposive sample selected from participants
who have given their consent to be approached about
the qualitative study when completing the online con-
sent form to take part in the trial. The invitation email
message for the qualitative study consists of an invitation
and participant information leaflet.
Consent
Potential participants are providing implied consent for
the INFORM Screening questionnaire by completing the
questionnaire and those who are eligible progress to on-
line informed consent for study entry. As part of the in-
formed consent participants provide consent to provide
a blood sample. When participants visit their general
practice to have their blood sample taken, practice staff
will take verbal consent for the procedure at the time of
the visit and this will be recorded in the patient notes.
The qualitative interview and focus group participants
will be asked to sign a paper consent form before the
start of the interview or focus group.
Baseline assessment
Baseline information is collected prior to randomisation.
Responders who are eligible to take part in the INFORM
study and provide informed consent are sent a welcome
email message with an individually tagged URL link to
the baseline online questionnaire (available from the au-
thors on request). Participants are requested to complete
this questionnaire within 7 days and receive reminder
email messages at day 7 and day 14. A reminder tele-
phone call will be made on day 16 if the questionnaire
still has not been completed. The measures assessed in
the baseline questionnaire are combined with several
measures taken during the participants’ INTERVAL
study assessment in order to characterise the study
population and to calculate individual’s phenotypic and
genetic risk scores.
For consenting participants in INFORM who took part
in physical activity monitoring in the INTERVAL study,
physical activity data will be shared between studies and
used as a baseline measurement for the INFORM study.
Participants who did not take part in physical activity
monitoring during the INTERVAL study are required to
undertake baseline physical activity monitoring over
7 days. The study team sends participants a watch-like
device (Axivity AX3 3-Axis Logging Accelerometer®) to
measure physical activity over a period of 7 days. The
device is sent together with instructions and a list of fre-
quently asked questions and responses to the questions.
A letter detailing the “switch on” and “switch off” date
(pre-set by the study team before posting) is included
with the device with instructions for return to the study
team in the freepost envelope provided. Participants are
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reminded by email to return their monitor 6 days after
the “switch off” date. If the monitor is not returned after
the email message is received, the helpdesk will attempt
to contact the participant by telephone or email. If a re-
sponse is still not received, a written request for the re-
turn of the monitor will be sent after 5 weeks. If the
monitor is still not returned after 6 weeks, the partici-
pant is randomised.
Randomisation, allocation concealment and blinding
Randomisation of the INFORM participants is under-
taken centrally at the trial coordinating centre at the
Department of Public Health and Primary Care, Univer-
sity of Cambridge. The study involves individual-level
randomisation using a computer program built into the
study database. This programme is designed and imple-
mented by the data manager. Randomisation is stratified
by age (≤ or > 60 years) and sex in order to balance base-
line phenotypic risk across study groups. Given the
nature of the trial, it is not possible to blind participants
to which intervention they receive. However, an inde-
pendent data manager (not involved in designing the
study) oversees the randomisation and data collection
process. Additionally, the researchers assessing the trial
outcomes will remain blinded to the allocation of inter-
ventions. As the participants for the qualitative part of
the study are purposively selected, the qualitative
researchers have access to the information collected
during baseline assessment and treat it as confidential.
Interventions
The study arms are summarised in Table 1. All partici-
pants will receive any information omitted from their
group allocation at the end of the follow-up period (this
includes the control group). The intervention in the
INFORM study consists of three components provided
to groups as described in Table 1: phenotypic CHD risk
score; genetic CHD risk score; and lifestyle advice.
Phenotypic CHD risk score
The phenotypic CHD risk score consists of three pieces
of information (Additional file 1A for example) as
adapted from a study by Persell et al. [27]. First, we pro-
vide participants with information on their absolute risk
of having CHD in the next 10 years, both as a percent-
age and as a natural frequency. We used the same set of
traditional CVD risk factors (age, sex, smoking status,
blood pressure, diabetes mellitus and total cholesterol
and high-density lipoprotein – HDL – cholesterol) as
used in many existing CVD risk scores [28] to calculate
the absolute risk of having either fatal or nonfatal CHD
events during the next 10 years. However, instead of ob-
jectively measured systolic blood pressure (as used in
existing CVD risk scores), we use self-reported informa-
tion on prescribed antihypertensive medication as a
proxy for blood pressure (since it is not logistically feas-
ible to collect objectively measured blood pressure in
this study). We therefore refined an existing validated
phenotypic CVD risk score [29] to take account of this
change in variable. In line with D’Agostino et al. [29], we
used sex-specific Cox proportional-hazards regressions
to relate risk factors to the incidence of first CHD event.
Correlates included in the Cox models were age, total
cholesterol (mmol/l), HDL cholesterol (mmol/l), antihy-
pertensive medication (self-reported yes/no), current
smoking (self-reported yes/no) and diabetes mellitus
(self-reported yes/no). All the continuous variables were
log-transformed. From these models, we estimated
mathematical CHD functions to predict 10-year risk of
CHD, using the general formula as published by D’
Agostino et al. [29].
Second, the absolute risk of having CHD in the next
10 years is accompanied by “Heart Age”. An individual’s
heart age is the chronological age of someone with the
same absolute risk of CHD but with healthy risk factors.
This means that individuals with elevated CHD risk fac-
tors will have a higher heart age than their chronological
age. The definition of “normal” is based on the following
profile: not a current smoker, does not have diabetes,
not using antihypertensive medication, total serum choles-
terol = 4.6548 mmol/l and HDL cholesterol = 1.1637 mmol/
l [30]. The “Heart Age” was derived from the same general
formula as used for the absolute risk score, rearranged such
that age is unknown, other risk factors are normal (as de-
fined above) and absolute risk is that of the participant in
question.
Finally, we provide participants with a comparative
risk estimate to encourage changes in health-related be-
haviours. An individual’s comparative risk is the risk of
someone who is the same age and sex and has healthy
lifestyle-related factors that are associated with CHD risk
[31, 32]. Healthy lifestyle-related factors were defined as
Table 1 Study Arms
Group Type Lifestyle advice Phenotypic risk score Genetic risk score
1 Control No No No
2 Intervention Yes No No
3 Intervention Yes Yes No
4 Intervention Yes Yes Yes
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follows: a) current non-smokers (i.e. never smoked and
former smokers) [33]; b) moderate levels of alcohol con-
sumption (one or more units a week but not more than
fourteen units a week; 1 unit = 8 grams) [33]; c) con-
sumption of fruit and vegetables (more than 400 grams)
[34]; d) consumption of fish (a portion size of 140 grams
cooked weigh (20 grams/day) [35]; e) consumption of
red meat (≤6 portions a week, equivalent to ≤500 grams
of cooked weight or 71 grams per day [36]; f ) physical
activity (not inactive, at least half an hour of leisure-time
activity a day) [33]; g) body mass index (BMI) <25 kg/m2.
All three pieces of information (absolute risk,
“Heart Age” and comparative risk) provided as part of
the phenotypic CHD risk score were modelled using
the data from the EPIC-Norfolk study [37]. This
means that we ran Cox proportional-hazards regres-
sions as described above in EPIC-Norfolk to get the
coefficients, but each INFORM participant’s values are
plugged in to these equations to get their 10-year risk
(Additional file 1B for example). As the outcome for
modelling, we have chosen CHD instead of CVD,
since the majority of genomic loci known to relate to
CVD are associated with CHD (rather than stroke)
and the study we used to estimate the coefficient for
our genetic risk score (EPIC-CVD) only has CHD
endpoints available currently. Given the fact that
CHD is the most common type of CVD the results of
INFORM study should be also applicable for CVD
risk communication.
Genetic CHD risk score
As with the phenotypic CHD risk score, the genetic
CHD risk information consists of three pieces of infor-
mation (Additional file 1C for example). First, we pro-
vide participants with the information on their absolute
risk of having CHD in the next 10 years. Second, infor-
mation on “Heart Age” is provided. Lastly, we provide
participants with a comparative risk estimate.
At the time of study design, there were 49 known gen-
omic loci robustly associated with risk of CHD [38]. We
selected lead variants at 46 of these regions that were in-
cluded on the Affymetrix “UK BioBank” Axiom genotyp-
ing array being used on INTERVAL participants, as well
as a customised version of the Illumina “Exomechip”
array that has been run in the EPIC-CVD study [39],
which was used to derive the risk estimates. EPIC-CVD
is a case-cohort study comprising of ~10,000 incident
CHD cases and a similar number of randomly selected
comparators. Participants who have been genotyped in
the INTERVAL study have a weighted genetic risk score
(GRS) estimated for them based on their genotypes at
each of the 46 relevant variants (Additional file 1D). This
means that for each individual, the number of CHD risk al-
leles (0/1/2) carried at each single nucleotide polymorphism
(SNP) was weighted by the strength (log of the odds ratio)
of that SNP’s association with risk of disease (to account for
the fact that not all variants have equal strengths of associ-
ation) and then summed across SNPs. Weights used were
drawn from the replication or combined estimates of asso-
ciation from the studies that originally discovered the vari-
ant associations [38, 40–42] . For estimation of the
association between the GRS and incident CHD outcomes,
the GRS was natural log-transformed (lnGRS). In line with
the phenotypic risk score, we estimated mathematical CHD
functions to predict 10-year risk of CHD using a similar
general formula. For the absolute genetic risk score, this
formula was plugged with the same baseline cumulative
hazard as the absolute phenotypic risk score, individual
lnGRS and the mean lnGRS. For the purpose of “Heart
Age”, normal lnGRS was defined as the sex-specific 10th
centile (<1.043 for males, <1.045 for females). For the pur-
pose of comparative risk estimate, healthy lnGRS was de-
fined as bottom 10 % of lnGRS (Additional file 1E for
example).
Format of phenotypic and genetic risk
Both CHD risk scores are presented in the same format
to ensure that the only experimental condition is the
addition of information on the risk of CHD based on
genetic variants (and not the different formats of pre-
senting the CHD risk information). In designing the
CHD risk scores we have taken into account the evi-
dence regarding the most effective methods for commu-
nicating CHD risk estimates [30, 43–46]. Based on this
evidence, INFORM participants are provided with: i) a
graphical format in the shape of a thermometer using
colours to distinguish risk (red, yellow, green) [47], ii)
“Heart Age” tool and iii) comparative risk information
[45, 47] (Additional file 1A and 1C for example). In
addition to the CHD risk estimates, we also provide par-
ticipants with an explanation of the factors included in
the calculation of their CHD risk scores, how to inter-
pret the thermometer and who to contact in case of any
questions, as well as a section with the answers to fre-
quently asked questions (adapted from a randomised
trial of personal genomics for preventive cardiology [48];
and from a study by Persell et al. [27]) in line with
previous evidence that participants expressed a need
to understand the numbers and values presented to
them [49].
Lifestyle advice
For the purpose of the INFORM study, we are using a
web-based lifestyle intervention for CHD prevention
based on an intervention that was originally developed
for the Heart to Health study [50]. The lifestyle interven-
tion consists of three sessions of interactive, tailored infor-
mation on the web (up to three hours of interventional
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contact). In previous studies, offering patients a risk-
reducing strategy was associated with increased adherence
and reduced CHD risk [51]. Therefore, a library of over
100 web pages providing advice on physical activity, diet,
smoking and medication are tailored according to partici-
pants’ selection of risk-reducing strategies (the web pages
are available from the authors on request). Each session
may last up to 60 min in duration depending on partici-
pants’ individual pace with sessions delivered at monthly
intervals. The first session begins with content-specific
education on diet, physical activity and smoking cessation.
This session also includes tips on how to overcome self-
identified barriers to risk reduction and the creation of
steps toward self-identified actionable goals. Sessions 2
and 3 include similar content; a participant begins by
reviewing their progress toward goals, continues with edu-
cation and tips to overcome barriers and finishes with
identification of new goals [50].
Follow-up assessment
Follow-up assessments take place at 12 weeks after ran-
domisation and include an online questionnaire, physical
activity monitoring and blood sample collection. Not all
of the measures in the baseline questionnaire are re-
peated at follow up (Table 2). The follow-up question-
naire (available from the authors on request) should take
no more than 20 min to complete. Participants are re-
quested to complete this follow-up questionnaire and
will receive two reminder emails at day 7 and day 14
after sending the follow-up questionnaire if it has not
been completed. If we do not hear from participants by
day 24, we will mark the data as missing.
Follow-up physical activity monitoring
All participants are requested to complete physical activ-
ity monitoring for 7 days at the 12-week time point fol-
lowing the same procedure as at baseline.
Blood sample
All participants are asked to provide a blood sample,
which is taken at their general practice. The blood sam-
ple is used to provide information on participants’ lipid
panel (total, HDL and low-density lipoprotein – LDL –
cholesterol; triglycerides), carotenoid levels and fructosa-
mine level. The study coordination team provides a
blood sample kit (Royal Mail Safebox™) which is sent to
participants along with the follow-up physical activity
monitor. The blood sample kit includes blood collection
tubes with barcoded, anonymised participant study
number, instructions for general practice clinicians, gen-
eral practice invoicing instructions and appropriate
packaging addressed to the receiving central laboratory
with pre-paid postage. A staff member at the partici-
pant’s general practice takes verbal consent for the
procedure at the time it is taken, writes the date and
time that the sample was taken on the blood collection
tube, packs the sample, and enters it into the postal de-
livery chain alongside regular practice post. Samples are
transported by Royal Mail first class mail to a central la-
boratory (UK BioCentre, Stockport, Cheshire, UK) that
logs and processes the samples. An email reminder mes-
sage to have a blood sample taken is sent 10 days after
the sample kit has been posted. The helpdesk attempts
to contact participants with outstanding blood samples
on days 17 and 28 after the sample kit has been posted,
and if the sample is not received after 31 days after the
sample kit has been posted, blood sample results will be
marked as missing data.
Measures
Table 2 provides details of the measures collected in the
INFORM study and the stage of the study at which each
is assessed. The primary outcome is objectively mea-
sured physical activity, defined as average acceleration
(m/s2) over the observation period. Participants are
instructed to continuously wear the accelerometer for 7
consecutive days and nights, and to carry on with all
normal activities during this time. The accelerometers
are waterproof and can be worn while swimming and
showering. Accelerometers have been chosen as a meas-
ure of physical activity because they cause low partici-
pant burden and are not subject to the reporting bias or
recall problems associated with the self-report methods
[52].
The key secondary outcome, dietary behaviour, is ob-
jectively measured by levels of six serum carotenoids
(alpha-carotene, beta-carotene, lutein, lycopene, beta-
cryptoxanthin, zeaxanthin). Carotenoids are biologically
active pigments in plants but are not synthesised in ani-
mals and as such they represent a valid biomarker of
vegetable and fruit intake [53].
Other objectively measured secondary outcomes in-
clude total, HDL and LDL cholesterol and fructosamine.
We also collect self-reported secondary outcomes via an
online questionnaire. They include cardiovascular risk
factors (self-reported weight, smoking status, alcohol
consumption, physical activity and dietary behaviour);
current medication and healthcare usage; perceived risk
(perception of comparative and absolute risk); cognitive
evaluation of provision of CHD risk scores (understand-
ing, accuracy, acceptability); and psychological outcomes
(anxiety associated with testing, fatalism, depression,
stress and mood).
As with any other intervention, it is important to
understand the mechanisms that explain why the
provision of CVD risk information leads to change or
not, and whether there are people with certain charac-
teristics who may benefit more or less from CVD risk
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Table 2 INFORM measures at each stage of the study
Measure or Instrument name INTERVAL INFORM
baseline
INFORM
follow-
up
Mode of
assessment
Note
Primary
outcome
Physical Activity Level* ✓ ✓ ✓ accelerometers using the Axivity AX3 – 3Axis logging
Accelerometer®
Secondary
outcomes
Traditional risk factors
Fruit and vegetables intake ✓ ✓ carotenoids
Weight ✓ ✓ self-report as used in Godino et al. [56] and Knowles et al. [48]
Cholesterol Panel (total, HDL
and LDL cholesterol,
triglycerides)
✓ ✓ blood serum
Fructosamine ✓ ✓ blood serum
Nutrition Behaviour (fruit,
vegetables, whole grains, fish,
red and processed meat)
✓ ✓ self-report one-item questions that reflect the present
prevention guidelines on CVD [16, 10]
Physical Activity Level ✓ ✓ self-report EPIC-Norfolk Physical Activity Questionnaire [60]
Smoking Status ✓ ✓ self-report
Alcohol Consumption ✓ ✓ self-report
Current Medication and
Healthcare Usage
✓ ✓ self-report adapted version of the Health Services Research
Unit Aberdeen questionnaire [61]
Perceived risk
Comparative and Absolute
Cardiovascular Risk
✓ ✓ self-report adapted according to Diefenbach et al. [62] and
used in other risk communication studies [48, 56]
Cognitive evaluation of provision
of coronary heart disease risk
scores
Understanding of Risk Scores ✓ self-report as used in another trial of risk communication [56]
Perceived Accuracy of Risk
Scores
✓ self-report as used in other risk communication studies
[48, 56]
Acceptability of the
Intervention
✓ self-report in line with the Heart to Health study [50]
Psychological outcomes
Stress ✓ ✓ self-report as used in the Randomized Trial of Personal
Genomics for preventive cardiology [48]
Mood ✓ ✓ self-report adapted from the Patient Health Questionnaire [63]
Coronary Heart Disease-related
Worry
✓ ✓ self-report an adaptation of the Cancer Related Worry
Scale [64]
Genetic Risk-related Worry/
Anxiety
✓ self-report as used by Knowles et al. [48]
Moderators
and
mediators
Sociodemographic
characteristics
Sex, Age, Ethnicity ✓ self-report
Marital Status ✓ self-report
Socioeconomic Status (level of
education, level of income,
living area)
✓ self-report adapted from the European Health Interview
Survey; deprivation level of the area based on the
Index of Multiple Deprivation, Department for
Communities and Local Government
Numeracy Skills ✓ self-report 3-item Schwartz scale [65]
Family History of Coronary
Heart Disease
✓ self-report
History of Genetic Testing ✓ self-report
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communication. To understand this, the following po-
tential moderators and mediators of the relationship be-
tween provision of risk information and behaviour
change are being measured as part of the INFORM
study: a) sociodemographic characteristics (ethnicity, so-
cioeconomic status, education, income, numeracy skills
and marital status); b) history of genetic testing and
CHD risk assessment; c) self-rated health; d) cognitive
and emotional theory-based antecedents to behaviour
change (behavioural intentions, perception of diet and
physical activity, beliefs about CVD, self-efficacy and re-
sponse efficacy, social support, mood and personality
characteristics); and f ) personal barriers to risk reducing
strategies.
Qualitative data collection
Qualitative interviews
An experienced qualitative researcher conducts in-depth
individual interviews with a sub-sample of trial partici-
pants starting soon after the randomisation and finishing
around 2–3 months after the 3-month follow-up period
is complete. Interviews cover issues related to the inter-
viewees’ experience of taking part in the trial; more spe-
cifically, their understanding of CHD risk, factors
affecting their understanding, reaction to receiving infor-
mation about risk and lifestyle advice, the extent to
which understanding of risk contributes to motivation
for behaviour change, the implementation of intention
to change after receiving risk information and lifestyle
advice, and the facilitators and barriers for such a
change. The qualitative study focuses mainly on partici-
pants in the intervention arms because the lack of an
intervention leaves little to discuss and explore qualita-
tively with the members of the control arm. However, in
order to explore the impact of receiving different types
of information in different stages, we aim to have up to
six interviews with members of arms who initially re-
ceived no intervention/only lifestyle advice/only pheno-
typic risk score, after they receive all their risk scores at
the end of the intervention.
In order to supplement the quantitative data which is
collected at only two time points (at baseline and
12 weeks later), we aim to interview different partici-
pants at different time points, interviewing some imme-
diately after the randomisation, others half way through
the intervention and others towards the end of the inter-
vention or up to 3 months after it ends. Proportionally
more participants whose risk score is medium or high
are purposively recruited as this is the population most
likely to have a stronger motivation to change their life-
style. A subset of this group may be interviewed more
than once – for example immediately after the start of
intervention and then after the completion of the inter-
vention in order to explore early expectations/motivation
and compare them with later perceptions or behaviour.
For the participants who do not express an intention to
Table 2 INFORM measures at each stage of the study (Continued)
History of Coronary Heart
Disease Risk Assessment
✓ self-report
Self-rated Health ✓ ✓ self-report Ware et al. [66]
Barriers to risk-reducing
strategy
✓ self-report in line with the Heart to Health study [50]
Cognitive and emotional
theory-based antecedents to
behaviour change
Intentions ✓ self-report adapted according to Ajzen [67] and used in
previous similar research [56]
Perception of Diet ✓ self-report
Perception of Physical Activity ✓ self-report
Coronary heart disease risk
Representations
✓ self-report the Brief Illness Perceptions Questionnaire [68]
Self-efficacy ✓ self-report as used in previous behavioural research [56, 68]
Response Efficacy ✓ ✓ self-report as used in previous behavioural research [52, 69]
Social Support ✓ self-report the Multidimensional Scale of Perceived Social
Support [70]
Time Orientation ✓ self-report as used in a study by Peretti-Watel et al. [71]
Sense of Coherence ✓ self-report 3-items scale, Lundberg et al. [72]
Comparative Optimism ✓ self-report comparative perceived risk
*participants who did not take part in physical activity monitoring during the INTERVAL Study will be required to undertake baseline activity monitoring
over 7 days
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change their lifestyle and those who are approached at
later stages of the intervention, the discussion on the reac-
tion to receiving the risk scores or lifestyle advice is con-
ducted retrospectively focusing on the period from
receiving the risk scores and up to the point of the inter-
view. Interviewees are asked to sign an interview consent
form giving permission for their interview to be recorded.
Qualitative focus groups
Two to three focus groups are conducted at different
points of time throughout the trial. Approximately 8–12
participants take part in each of the focus groups. These
participants do not take part in the individual qualitative
interviews. The focus groups are facilitated by an experi-
enced qualitative researcher and one or two assistants
from the research team. Participants are purposively se-
lected in order to include people with various demo-
graphic backgrounds. However, at least two of the
groups may be selected for gender homogeneity (male/
female-only) in order to encourage greater participation
in what may be considered a gender-sensitive issue. The
focus groups cover issues related to the relationship be-
tween risk awareness, motivation for change and actual
change of behaviour and lifestyle, but their main focus is
on communication and understanding of CHD risk esti-
mates as well as the lifestyle advice. We hope to benefit
from the interactive aspect of the focus groups in order
to gain as rich as possible feedback regarding the advan-
tages and disadvantages of the forms of communication
of risk and lifestyle advice used in the trial. Permission is
sought from the participants, as outlined in the consent
process, for the focus groups to be recorded and
transcribed.
Withdrawal
A participant is free to withdraw their consent from the
study, at any time, without giving a reason. All requests
from participants to withdraw from the study are di-
rected to the study coordination team who will discuss
the options for withdrawal. The study data manager
places a flag on the research database to ensure appro-
priate use of data and notifies the study coordination
team of withdrawal. University of Cambridge research
staff instructs the central laboratory to remove all arch-
ive samples from the biorepository for participants who
have been withdrawn from the study and who have re-
quested no further use of their stored samples.
Adverse events
This is a low-risk trial with little reason to consider that
adverse events would arise as a result of following any of
the interventions. Accordingly, no formal adverse event
monitoring is planned. However, events may incidentally
come to the attention of the research team (e.g. via
interviews or focus groups, or direct communication
with participants via the study coordination team) which
will be recorded and followed up accordingly.
Statistical analyses
Sample size calculation – randomised controlled trial
The primary outcome is between-group differences in
the change (follow-up minus baseline) of the average ac-
celeration (m/s2) over the observation period, measured
using the Axivity AX3 3-Axis Logging Accelerometer®.
The intervention will be potentially important if it in-
creases the primary outcome by 10 %. This corresponds
to an additional 10 min of brisk walking per day or an
additional 3 min of jogging per day. The same effect size
was used in the Understanding Risk trial by Price et al.
[54] among people at high risk of CVD with one month
of follow-up. This effect size is also in line with the Pro-
Active trial that aimed to increase physical activity
among individuals at high risk of type 2 diabetes [55].
To allow for four pairwise comparisons in the primary
analysis, the significance level was set to 1.25 %. We cal-
culated that 186 participants per group will be needed to
detect this effect with 80 % power and 95 % confidence,
assuming the estimated standard deviation (SD) of
change in physical activity from baseline to follow-up is
0.05 and the correlation between physical activity at
baseline and follow-up is 0.6 [56]. Allowing for an attri-
tion rate of 20 %, we therefore aim to randomise a total
of 932 participants (233 per group).
Sample size – qualitative study
A sample size of between 30 and 35 male and female
participants will be selected purposively, mainly from
the intervention arms to include people with various
demographic backgrounds. This sample size is common
for this kind of study [57, 58] and is consistent with the
time resources required for this type of data analysis and
the predicted range of number of interviews required for
achieving saturation.
Analysis design – randomised controlled trial
All trial analyses will be based on the Intention To Treat
(ITT) principle. Those with missing follow-up data will
be excluded from the analyses (a complete case ap-
proach). We will perform sensitivity analyses to assess
the impact of missing follow-up data on the results. Par-
ticipants with missing baseline data will be included in
the analyses using the missing-indicator method [59].
The null hypothesis for the primary analysis is that
there is no difference between any of Groups 1 to 4. Es-
timates of the following pairwise differences will be cal-
culated: 1) Group 1 (control group) vs. Group 2 (lifestyle
advice only) – to estimate the effect of providing lifestyle
advice compared with no intervention; 2) Group 3
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(phenotypic risk score and lifestyle advice) vs. Group 4
(phenotypic and genetic risk scores and lifestyle advice)
– to estimate the effect of providing a genetic risk score
in addition to lifestyle advice and a phenotypic risk
score; 3) Group 3 + Group 4 vs. Group 1 – to estimate
the effect of providing risk score information and life-
style advice compared with no intervention, and 4)
Group 3 + Group 4 vs. Group 2 – to estimate the effect
of providing risk score information in addition to life-
style advice.
Mean changes in objectively measured physical activity
between baseline and 3-month follow-up will be ana-
lysed using analysis of covariance (ANCOVA). The
ANCOVA model will model change (follow-up minus
baseline) in objectively measured physical activity, ad-
justed for baseline. A test involving three degrees of free-
dom (3 d.f.) will be performed of the null hypothesis
that there is no difference between the four randomised
groups. If the p-value from this test is <0.01, this will
imply that there are differences between the groups. The
ANCOVA model will also be used to derive estimates of
the differences in mean change and 95 % confidence in-
tervals for each of the four pairwise comparisons de-
scribed above. To avoid detracting the focus of the
results from the overall 3 d.f. test, p-values for each of
the pairwise comparisons will not be calculated.
For each continuous secondary endpoint, the four
pairwise differences will be estimated, together with
95 % confidence intervals, using ANCOVA as described
for the primary outcome analyses (except Coronary
Heart Disease-related Worry). The Coronary Heart
Disease-related Worry will be measured only at follow-
up, so the four pairwise differences will be estimated, to-
gether with 95 % confidence intervals, using linear re-
gression. A 3 d.f. test will be performed of the null
hypothesis that there is no difference between the four
randomised groups. For categorical endpoints, similar
analyses will be performed using logistic and multi-
nomial regression models.
Subgroup analyses
For the primary endpoint, the ANCOVA model will be
extended to include an interaction between the interven-
tion effect and (1) age (continuous variable), (2) baseline
phenotypic CHD risk score (continuous variable) and (3)
sex. If the p-value for interaction is <0.05, then the num-
ber and percentage of individuals with the endpoint
within each randomised group, together with interven-
tion effect (and 95 % confidence intervals) will be re-
ported separately within categories defined by the
subgroup variable. For age and baseline CHD risk score,
the cut-off for the categories will be their median values
at baseline.
Multiplicity
Given the number of endpoints, randomised groups and
therefore comparisons, the results for the primary end-
point will be regarded as convincing if the p-value from
the 3 d.f. test is <0.01, while the results for each second-
ary endpoint will be regarded as convincing if the rele-
vant p-value from the 3 d.f. test is <0.001.
Qualitative analyses
Thematic analysis will be used to analyse the qualitative
data. The transcriptions will be coded using NVivo soft-
ware. To increase the rigour and validity of the analysis,
and as a form of triangulation, the framework develop-
ment (coding tree) will be conducted by a subgroup of
three members of the team (the lead qualitative re-
searcher and two others). In addition, a subset of 20 %
of transcripts will be double-coded by two members of
the research team, and disagreements will be discussed
in order to reach consensus about interpretation and
indexing. Analysis will involve two stages:
(1)Data management which will include: a)
familiarisation with the data, including reading
transcripts and notes and/or listening to the audio
dialogue in order to extract main themes and ideas;
b) thematic framework development, identifying the
key issues and concepts present in the data and
creating a coding tree which will be conducted both
inductively, based on the data, and deductively,
based on the research questions; c) indexing the
data.
(2)Interpretation stage which will include focused or
axial coding, defining the main concepts and
mapping the ways in which different parts of the
data are related to each other.
Discussion
The INFORM randomised trial has been designed to
contribute toward the understanding of the impact of
provision of phenotypic and genetic CHD risk information
on health-related behaviour change and other important
clinical outcomes. Comparison between randomised trial
arms will enable estimation of: 1) the effect of providing
web-based lifestyle advice; 2) the effect of providing a gen-
etic risk score in addition to lifestyle advice and a pheno-
typic risk score; 3) the effect of providing risk score
information and lifestyle advice and 4) the effect of
providing risk score information in addition to lifestyle
advice. The INFORM study will also provide information
on potential moderators and mediators between the inter-
vention and health-related behaviour change and other
clinical outcomes.
Even though the routine use of CVD risk scores is
strongly advocated by most cardiovascular guidelines
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[10, 11], relatively little is reliably known about the bene-
fits of the provision of different forms of CVD risk
scores to individuals and about any potential harms
(such as the possibility of increased anxiety or false re-
assurance). Previous systematic reviews [18, 19] have
concluded that no robust recommendations can be
made about the value of providing CVD risk information
owing to limitations in previous studies, including lack
of adequate power and lack of objective measures of
health-related behaviours.
The INFORM study is well-placed to advance current
knowledge on this topic because it is a trial that com-
bines several advantages, including: a) power to identify
clinically important differences between groups in this
study’s principal outcomes; b) objective measures of
health-related behaviours; c) simplicity of the interven-
tions and relevance to primary care. If the interven-
tion(s) in this trial prove to be effective, then the
components of the intervention should be relatively easy
to implement in primary care practice. Hence, the IN-
FORM trial should provide a reliable evaluation of the
impact of the provision of CVD risk information,
thereby potentially informing policy decisions and guid-
ing clinical practice about the routine use of CVD risk
scores in primary care.
Research governance
Ethical approval
Ethical approval was received from NRES Committee
East of England – Cambridge Central (14/EE/1164) on
03/12/2014. NHS Research and Development assurance
has been received by our lead CCG (Cambridgeshire and
Peterborough CCG) and CRN: Eastern. The trial was
prospectively registered at the ISRCTN Registry
(ISRCTN17721237) on 12/01/ 2015. This paper details
version 1.2 of the trial protocol dated 13/01/2015. The
trial has been adopted by the NIHR Portfolio.
Study sponsor
The University of Cambridge is the sponsor of this trial.
Data handling and quality assurance
A Data Monitoring Committee is not considered appro-
priate for this trial considering that the likely risks to
participants are known to be minimal, recruitment and
follow-up are over a short period of time, and the data
for this trial is both collected and stored online and, as
such, is expected to have a minimal error rate. Any inciden-
tal safety information will be reported to the Trial Steering
Committee (TSC). The Data Manager is responsible for the
quality and integrity of data and will provide a data report
to each TSC meeting. Data are stored in accordance with
the University of Cambridge School of Clinical Medicine
Information Governance policy which relates to sensitive/
identifiable personal information collected and stored for
the purposes of research.
Patient and public involvement (PPI)
Two representatives from the PPI Panel at Cambridge
University Hospitals NHS Foundation Trust were re-
cruited in June 2014. PPI representatives have played an
integral role in the INFORM study and contributed to
the different stages of the research. More specifically,
PPI representatives commented on the protocol, ques-
tionnaires, wording and format of the presentation of
the risk score estimates, critically revised patient infor-
mation sheets (both qualitative and quantitative) as well
as the web-based lifestyle intervention. PPI representa-
tives have a central role in the TSC. We expect that they
will also be involved with developing newsletters and
taking part in dissemination activities.
Trial oversight
In addition to the Research Ethics Committee, the IN-
FORM study is overseen by the TSC and Trial Manage-
ment Group (TMG). The purpose of the TSC is to
provide oversight of the clinical trial, with particular ref-
erence to adherence to the protocol, compliance with
the Department of Health Research Governance Frame-
work and the Guidelines for Good Clinical Practice, and
the rights, safety and wellbeing of the trial participants.
In addition to members of the research team, the
Committee contains a number of independent members,
specifically the Independent Chair, Independent
Academics and PPI representatives. The purpose of the
TMG is to monitor the objectives and progress of the
trial, oversee day-to-day management of the study, con-
sider any new information that may be relevant to the
trial and discuss any scientific matters contained in, or
relevant to, the trial. It includes investigators, the trial
manager and project administrative assistant.
Research dissemination and data preservation for sharing
The investigators will analyse data according to a prede-
fined analysis plan in a timely manner. Members of the
research team will be involved in reviewing drafts of the
manuscripts, abstracts, and any other publications aris-
ing from the trial. The Chief Investigator will have final
approval on all publications and press releases. Author-
ship of publications will be determined by ICMJE guide-
lines. A lay summary of the research findings will be
available on the study website [29] and study partici-
pants will be notified by email when they are available.
The database manager will take responsibility for data
curation and archiving, and all data sets will be kept se-
curely with no access from unauthorised personnel. Data
will be stored so that it can be accessed, used and under-
stood by subsequent users. On completion of the data
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collection we will develop a data dictionary so that sci-
entists can request release of a study dataset from the
investigators. When the investigators have completed
their planned analyses, the anonymised data will be
made available for use by others and will be shared
under appropriate data sharing agreements. Primary data
and the Trial Master File will be retained securely in
their original form for a minimum of 10 years.
Trial status
Ongoing. Recruitment was completed in June 2015.
Additional file
Additional file 1: Appendix A. An example of presentation of
phenotypic coronary heart disease risk score. Appendix B. Mathematical
coronary heart disease functions to predict 10-year risk of coronary heart
disease. Appendix C. An example of presentation of genetic coronary
heart disease risk score. Appendix D. INFORM SNPs for genetic risk score.
Appendix E. Mathematical formulas for calculation of risk estimates
based on genetic risk score (GRS). (ZIP 112 kb)
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